Instylla HES Hypervascular Tumor Pivotal Study

NACompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

May 1, 2024

Study Completion Date

November 19, 2024

Conditions
Hypervascular Tumors
Interventions
DEVICE

Instylla HES

Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)

OTHER

TAE or cTACE

Bland TAE or cTACE

Trial Locations (15)

10065

New York and Presbyterian Hospital (Cornell/Weill Medical College), New York

15213

University of Pittsburgh, Pittsburgh

28202

Charlotte Radiology, Charlotte

35233

UAB Hospital, Birmingham

41017

St. Elizabeth Healthcare, Edgewood

72205

Central Arkansas Radiation Therapy Institute, Inc., Little Rock

92708

Memorial Health Services, Long Beach

92697- 7600

University of California, Irvine, Irvine

91342-1495

Olive View-UCLA Education & Research Institute, Sylmar

02118

Boston Medical Center, Boston

07932

Summit Health, Florham Park

19104-6061

University of Pennsylvania, Philadelphia

M4N 3M5

Sunnybrook Research Institute, Toronto

M5G 1Z5

Mount Sinai, Toronto

M5G 2C4

Toronto General Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Instylla, Inc.

INDUSTRY